EASL Recommendations on Treatment of Hepatits C 2016
A message from EASL (European Association for the Study of the Liver)
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 180 million, but most are unaware of their infection. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.
Read more »
CMV Drug Development Forum Publication: Definitions of CMV infection and disease in transplant patients for use in clinical trials
The report “Definitions of CMV infection and disease in transplant patients for use in clinical trials” is now available for advance access online in Clinical Infectious Diseases ( http://cid.oxfordjournals.org/content/early/2016/09/27/cid.ciw668.abstract)
Read more »
UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C
A message from UNITAID and FIND.
UNITAID Media Contact: Andrew Hurst, Director of Communications FIND Media Contact: Julie Archer, Senior Communications Officer
GENEVA - UNITAID today announced a partnership with FIND to improve diagnostics and treatments for hepatitis C virus (HCV) and make them more affordable and widely available to those in need.
The US $38.3 million project will support the development of better, simpler, diagnostic tools for HCV where people seek care, and will introduce HCV testing and treatment over three and a half years in HIV programmes in seven countries: Cameroon, Georgia, India, Malaysia, Myanmar, Thailand and Vietnam.
Until recently, treatment of HCV was complex, lengthy and of limited efficacy. In addition, severe side effects made it difficult for some to complete the full course of treatment, which could take a year or more.
New medicines for the treatment of HCV, in the form of direct acting antivirals (DAAs), have revolutionized HCV treatment in recent years. Combinations of these new medicines, which are generally well tolerated and highly effective, can cure HCV in as little as 12 weeks, compared with the older, year-long regimens.
Read more »
NIH Announces New DAIDS Policy Website
The National Institute of Allergy and Infectious Diseases (NIH) Announces the new DAIDS policy website.
The Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases (NIAID) is informing its stakeholders of the launch of the newly redesigned NIAID website. The new website has a clean uncluttered design, improved functionality and enhanced rich content
Read more »
EATG Press Release: The 2016 Annual General Assembly
PRESS RELEASE Brussels, 27 September 2016
Closing an incredibly successful year with massive steps towards implementing the long-term strategy and mission, and the addition of 4 new major projects, The European AIDS Treatment Group (EATG) met in Sofia, Bulgaria for its annual general assembly, and the election of two new members of the Board of Directors on 23-25 September 2016.
The European AIDS Treatment Group (EATG – www.eatg.org), one of the largest networks of treatment activists, people living with, affected by and at risk from HIV, and their supporters in Europe held its annual General Assembly and elections between 23 and 25 September 2016. More than 80 EATG members from the HIV/AIDS field gathered in Sofia, Bulgaria in order to discuss the achievements and challenges of the year 2015, the long-term vision of the EATG, and to elect two new members for the Board of Directors.
Read more »
New Guidance from AASLD: Test for HBV Before Starting DAAs for HCV
A message from AASLD (American Association for the Study of Liver Diseases)
All patients beginning hepatitis C (HCV) treatment using direct acting antiviral (DAA) therapies should be assessed for hepatitis B (HBV), according to the AASLD/Infectious Diseases Society of America (IDSA) Guidance Panel. The AASLD/IDSA Recommendations for Testing, Managing and Treating Hepatitis C have been updated to include this new practice guidance.
Read more »
HHS Office of HIV/AIDS and Infectious Disease Policy (OHAIDP): Viral Hepatitis Updates
Viral Hepatitis Updates from the HHS Office of HIV/AIDS and Infectious Disease Policy (OHAIDP)
HHS Viral Hepatitis Website Launch As part of efforts to increase awareness of viral hepatitis in May, Hepatitis Awareness Month, OHAIDP launched a new, dedicated HHS viral hepatitis page at HHS.gov/hepatitis! This new website will enable OHAIDP to expand commitment to fostering partnerships and action in the fight against viral hepatitis. OHAIDP is continuing to add resources and content for and about viral hepatitis while working to amplify viral hepatitis updates, policies, and partners’ work. You are encouraged to visit the new website and check out recent blogs, learn more about viral hepatitis, and learn how to get involved. Be sure to check back often, as blogs, announcements, and resources are being continually updated.
Read more »
European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada For Reducing the Risk of Sexually Acquired HIV-1
– Truvada is the First Antiretroviral Medicine to be Licensed in Europe for Pre-Exposure Prophylaxis, in Combination with Safer-Sex Practices, to Reduce the Risk of Sexually Acquired HIV-1 in Adults at High Risk –
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 22, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Truvada(emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination with safer-sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis, or PrEP. Truvada was approved by the European Medicines Agency in 2005 for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults aged 18 years and over, and is currently the most prescribed antiretroviral medicine in Europe as part of combination therapy.
The marketing authorization allows for the marketing of Truvada for PrEP in all 28 countries of the European Union, subject to national regulatory authority approval of required pharmacovigilance materials in each country.
Read more »
AIDS 2016: Progress and Challenge
A report from IDSA Global Health
When the 2000 International AIDS Conference convened in Durban, South Africa, the government of the host country denied existence of the virus, and, worldwide, just 700,000 of an estimated 30 million people living with HIV were receiving the antiretroviral treatment they needed to stay alive.
The 2016 International AIDS Conference returned to the South African city and to a country that is home to the largest HIV treatment program in the world, while more than 17 million people globally are accessing antiretroviral treatment.
Still, with an estimated 37 million people living with HIV worldwide, the world faces the need to ensure treatment for at least 20 million more. Prisoners, men who have sex with men, transgender women, people engaged in sex work, and people who inject drugs remain at disproportionately high risk for HIV, with disproportionately low access to services. Women continue to surpass men in new infections, while men, behind in diagnosis and treatment, surpass women in AIDS-related deaths. And still, fewer than one in three of the 2.6 million children living with HIV are accessing antiretroviral treatment. With all of these challenges now, discussions noted, the future holds the prospect of the largest generation in history approaching the age of greatest risk for HIV.
Read more »
EATG Press Release: 25 years of change in HIV research - the foundations of treatment activism in Europe
PRESS RELEASE Brussels/Berlin, 29 July 2016
The European AIDS Treatment Agenda - the first international catalogue of patients' demands and principles in research - originated in 1991. EATA was signed by the major European AIDS Service Organisations. EATA was the basis for the foundation of EATG in 1992. EATG celebrates the 25th anniversary of European treatment activism by publishing historic documents.
These 25 years have seen substantial changes in HIV activism and advocacy. One of the key outcomes from the early days of this work is the establishment and operation of the European AIDS Treatment Group (EATG), one of the largest networks of people living with and affected by HIV in Europe.
Read more »
|
|